SAB Biotherapeutics

A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.

SAB Biotherapeutics headquartered in United States, North America, operates in the Biotechnology, Therapeutics, Clinical Trials sector. The company focuses on Biotechnology and has secured $15.7B in funding across 84 round(s). With a team of 51-100 employees, SAB Biotherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - SAB Biotherapeutics, raised $1.4M. Discover more about their projects, partnerships, and impact on our platform.